Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares jumped on Friday after the firm announced an update from the U.S. Food and Drug Administration (FDA).
Specifically, the FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Karyopharm’s selinexor. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor.
The previously disclosed April 6, 2019, PDUFA date has been extended by three months to July 6, 2019.
Selinexor, in combination with dexamethasone, is a treatment for patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.
While the extension of the PDUFA date might be seen as a mixed blessing, the FDA’s Oncologic Drugs Advisory Committee met late February to discuss the selinexor NDA and voted eight to five recommending that the FDA wait for the results from Karyopharm’s Phase 3 study before making a final decision regarding approval.
Although the FDA considers the recommendation of this panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding.
Shares of Karyopharm were last seen up about 15% at $5.06 on Friday, in a 52-week range of $3.92 to $21.71. The stock has a consensus price target of $15.78.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
